The Claudin 18.2 test is a highly specialized diagnostic tool, offering precise identification of the Claudin 18.2 protein, a ...

This technique has further allowed early HIV diagnosis. Other advantages of fourth-generation high-throughput assays are ...

Becton Dickinson's HPV assay was FDA-approved for use with clinician-collected samples in 2018 and received approval for sample self-collection in May.

A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far ...

Consequently, the Court refused to quash the final report alleging offence punishable under Section 336 (rash or negligent ...

Plus Therapeutics subsidiary CNSide Diagnostics has reported data from the multi-centre FORESEE trial, which highlights the ...

Scientists at the University of Florida have developed a pioneering tool to bolster Florida’s defenses against invasive ...

SAGA ("SAGA" or the "Company"), a North American exploration company focused on critical mineral discovery in Canada, is ...

More than three years into a lawsuit accusing competitor Natera of disparaging its cancer blood test, Guardant Health has ...

level by the US FDA's new in vitro diagnostic multivariate index assay classification, is offered as a prognostic test for women under the age of 61 years with either estrogen receptor-positive or ...

The company, based outside of Grenoble in the French Alps, together with its partners has received €5 million to pursue the project.

November 26, 2024) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) (the "Company" or "Doubleview") is pleased ...